SERNYSE

Serina Therapeutics, Inc.

Healthcare·Neurology·Phase 1·Huntsville, AL, United States
Neurology

Serina Therapeutics, Inc. (SER): 3 pipeline candidates · ~17 mo cash runway · 1 clinical trial. Updated within the last hour.

5.1/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway4.6

16.5 months

Financial Health10.0

0% dilution

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider Signal1.1

3 buys · 12 sells (180d)

A transparent, data-derived signal for Serina Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$29.2M

Cash

$24.5M

Quarterly Burn

$4.6M

Runway

16.5 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Nov 2027
Today~18 mo out
Catalyst within runway

Pipeline (3 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

21

Total value held

$1.0M

HolderSharesValue
vanguard capital management llc318,272$617K
geode capital management, llc64,973$126K
blackrock, inc.58,264$113K
jane street group, llc39,653$77K
vanguard fiduciary trust co20,009$39K
state street corp12,758$25K
caitong international asset management co., ltd3,982$8K
wells fargo & company/mn3,606$7K
osaic holdings, inc.1,001$2K
tower research capital llc (trc)843$2K

Showing top 10 of 21 institutional holders of Serina Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

1 clinical trial·2 FDA decisions·CEO: Mr. Steven A. Ledger

Frequently asked questions

How many drug candidates are in Serina Therapeutics, Inc.'s pipeline?

Serina Therapeutics, Inc. (SER) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Serina Therapeutics, Inc.'s lead drug candidate?

Serina Therapeutics, Inc.'s most advanced tracked candidate is ser 214 (Phase 1) for Early Parkinson's and Restless Leg Syndrome.

What is Serina Therapeutics, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Serina Therapeutics, Inc. has approximately 16.5 months of cash runway.

What is Serina Therapeutics, Inc.'s market capitalization?

Serina Therapeutics, Inc.'s market capitalization is approximately $29.2M.

Who is the CEO of Serina Therapeutics, Inc.?

Mr. Steven A. Ledger is the chief executive officer of Serina Therapeutics, Inc. (SER).

Get the full picture on Serina Therapeutics, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.